Abstract
Background: Kawasaki disease shock syndrome is a rare presentation of Kawasaki disease, in which cardiovascular manifestations associated with elevated inflammation biomarkers that develop hypotension are observed. It is preceded by gastrointestinal and neurological manifestations, with an increased risk of coronary lesions and resistance to intravenous immunoglobulin.
Case report: A 5-month-old male patient with a fever that had developed in the last week, gastrointestinal and neurological symptoms with hypotensive shock, urticarial rash, BCG lymphadenitis, and edema of palms and soles. Giant coronary aneurysms were evident, so Kawasaki disease shock syndrome was diagnosed, which was treated with corticosteroid pulse and intravenous immunoglobulin.
Conclusions: Clinicians must suspect Kawasaki disease shock syndrome when there is hypotensive shock, and the gastrointestinal, neurological and mucocutaneous symptoms that are characteristic of the disease, especially in infants under one year of age. The timely treatment of this disease reduces severe complications
References
Taubert KA, Rowley AH, Shulman ST. Seven-year national survey of Kawasaki disease and acute rheumatic fever. Pediatr Infect Dis J. 1994;13(8):704-708. DOI: 10.1097/00006454-199408000-00005
McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999. DOI: 10.1161/cir.0000000000000484
Gámez-González LB, Murata C, Muñoz-Ramírez M, Yamazaki-Nakashimada M. Clinical manifestations associated with Kawasaki disease shock syndrome in Mexican children. Eur J Pediatr, 2013;172(3):337-342. DOI: 10.1007/s00431-012-1879-1
Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Pancheri J, Tremoulet, AH, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009;123(5):e783–e789. DOI: 10.1542/peds.2008-1871
Grignani R, Quek SC. Kawasaki disease in 2019-past controversies, present insights and future directions. Pediatr Med. 2019;2:10. DOI: 10.21037/pm.2019.03.03
Gámez-González LB, Hamada H, Llamas-Guillen BA, Ruiz-Fernández, M, Yamazaki-Nakashimada M. BCG and Kawasaki disease in Mexico and Japan. Hum Vaccin Immunother, 2017;13(5):1091-1093. DOI: 10.1080/21645515.2016.1267083
Garrido-García LM, Castillo-Moguel A, Vázquez-Rivera M, Cravioto P, Fernando G. Reaction of the BCG scar in the acute phase of Kawasaki disease in Mexican children. Pediatr Infect Dis J. 2017;36(10):e237-e241. DOI: 10.1097/inf.0000000000001633
Salgado AP, Ashouri N, Berry EK, Sun X, Jain S, Burns JC, et al. High risk of coronary artery aneurysms in infants younger than 6 months of age with Kawasaki disease. J Pediatr. 2017;185:112-116.e1. DOI: 10.1016/j.jpeds.2017.03.025
Cimaz R, Sundel R. Atypical and incomplete Kawasaki disease. Best Pract Res Clin Rheumatol. 2009;23(5):689-697. DOI: 10.1016/j.berh.2009.08.010
Gámez-González LB, Moribe-Quintero I, Cisneros-Castolo M, Varela-Ortiz J, Muñoz-Ramírez M, Garrido-García M, et al. Kawasaki disease shock syndrome; a unique and severe subtype of Kawasaki disease. Pediatr Int. 2018;60(9):781-790. DOI: 10.1111/ped.13614
Gamillscheg A, Zobel G, Karpf EF, Dacar D, Beitzke A, Stein JI, et al. Atypical presentation of Kawasaki disease in an infant. Pediatr Cardiol. 1993;14(4):223-226. DOI: 10.1007/bf00795375
Johnson PN, Kuhn RJ. Combination thrombolytic and anti-platelet therapies in an infant with incomplete Kawasaki disease and coronary aneurysms. J Pediatr Pharmacol Ther. 2008;13(4):242-250. DOI: 10.5863/1551-6776-13.4.242
Watanabe T. Shock following administration of contrast medium in a patient with Kawasaki disease. Pediatr Radiol. 2010;40(7):1304-1305. DOI: 10.1007/s00247-010-1574-1
Thabet F, Bafaqih H, Al-Mohaimeed S, Al-Hilali M, Al-Sewairi W, Chehab M. Shock: an unusual presentation of Kawasaki disease. Eur J Pediatr. 2011;170(7):941-943. DOI: 10.1007/s00431-011-1426-5
Gatterre P, Oualha M, Dupic L, Iserin F, Bodemer C, Lesage F, et al. Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome. Intensive Care Med. 2012;38(5):872-878. DOI: 10.1007/s00134-012-2473-8
Chen PS, Chi H, Huang FY, Peng CC, Chen MR, Chiu NC. Clinical manifestations of Kawasaki disease shock syndrome: a case-control study. J Microbiol Immunol Infect. 2015;48(1):43-50. DOI: 10.1016/j.jmii.2013.06.005
Del Monte MEA, González LRH, García DM, Yamazaki NM, Huerta LJG. Síndrome de choque tóxico por enfermedad de Kawasaki: reporte de un caso en paciente de 10 meses de edad. Alerg Asma Inmunol Pediatr. 2016;25(1):30-33. Disponible en: https://www.medigraphic.com/pdfs/alergia/al-2016/al161e.pdf
Ma L, Zhang YY, Yu HG. Clinical manifestations of kawasaki disease shock syndrome. Clin Pediatr (Phila). 2017;57(4):428-435. DOI: 10.1177/0009922817729483
Lin Y, Shi L, Deng Y, Liu Y, Zhang H. Kawasaki disease shock syndrome complicated with macrophage activation syndrome in a 5-month old boy. Medicine (Baltimore). 2019;98(4):e14203. DOI: 10.1097/md.0000000000014203
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2020 Revista Alergia México